{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:38:16Z","timestamp":1790199496899,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune thrombotic thrombocytopenic purpura (iTTP) is a rare but fatal hematologic disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and multiorgan dysfunction. Early diagnosis and prompt treatment, including plasma exchange (PE), corticosteroids, and rituximab (RTX), are critical for improving outcomes. However, real-world emergency management experiences for first-episode iTTP remain understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study analyzed 96 patients with first-episode iTTP admitted to the emergency department of Peking University People\u2019s Hospital between 2004 and 2024. Baseline characteristics, clinical features, treatment modalities, and outcomes were evaluated. Logistic and Cox regression analyses were conducted to identify predictors of clinical response and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the enrolled patients, the median age was 45 years and 54.2% were female. The comorbidities included rheumatologic and antoimmune diseases (28.1%) and cancer (11.5%). The mortality rate was 38.5% whereas the relapse rate was 13.6% in survival group. RTX administration increased over time (0% in 2004\u20132010 vs. 51.9% in 2018-2024) and was associated with improved survival (HR = 0.27, 95% CI: 0.11-0.66). Corticosteroid pulse therapy was an independent predictor of clinical response (OR = 2.8, 95% CI: 1.1-7.6). Independent predictors for mortality included age over 45 years (HR = 5.5, 95% CI: 2.1-14.3), pentad symptoms (HR = 3.5, 95% CI: 1.5-8.4), and lactate dehydrogenase over 1500 U\/L (HR = 2.7, 95% CI: 1.2-5.8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlighted the importance of early RTX and corticosteroid pulse therapy in the emergency management of first-episode iTTP. We also provide a risk stratification framework for emergency clinicians, guiding more prompt and effective management as well as personalized therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1645558","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:40:23Z","timestamp":1768372823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Experience in emergency management of first-episode immune thrombotic thrombocytopenic purpura over the past 21 years: a single-center retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Liqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maojing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17474086.2023.2159803","article-title":"An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura","volume":"16","author":"G\u00f3mez-Segu\u00ed","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030621","article-title":"Pathological mechanisms and novel testing methods in thrombotic thrombocytopenic purpura","volume":"12","author":"Dolin","year":"2024","journal-title":"Biomedicines"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03552-8","article-title":"Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura","volume":"117","author":"Kubo","year":"2023","journal-title":"Int J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac034","article-title":"European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis","volume":"37","author":"Eller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05634-x","article-title":"Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut","volume":"103","author":"Vegas Villalmanzo","year":"2024","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1668545","article-title":"Relapse rate in survivors of acute autoimmune thrombotic thrombocytopenic purpura treated with or without rituximab","volume":"118","author":"Falter","year":"2018","journal-title":"Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan","volume":"106","author":"Matsumoto","year":"2017","journal-title":"Int J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03197-5","article-title":"Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"114","author":"Kayashima","year":"2021","journal-title":"Int J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01775-1","article-title":"Clinical profile, treatment and outcome of thrombotic thrombocytopenia purpura (TTP) in rituximab era- an experience from tertiary care centre from north India","volume":"40","author":"Gupta","year":"2024","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000748","article-title":"Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival","volume":"134","author":"Prevel","year":"2019","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00881-3","article-title":"Hallmarks of cardiovascular ageing","volume":"20","author":"Abdellatif","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1098-1101(1998)13:1%3C16::aid-jca3%3E3.0.co;2-c","article-title":"Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura","volume":"13","author":"Cohen","year":"1998","journal-title":"J Clin Apher"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2022-141573","article-title":"High level of lactate dehydrogenase and ischaemia\u2013reperfusion injury regulate the multiple organ dysfunction in patients with COVID-19","volume":"99","author":"Ashraf","year":"2023","journal-title":"Postgrad Med J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18040","article-title":"TTP: From empiricism for an enigmatic disease to targeted molecular therapies","volume":"197","author":"Gra\u00e7a","year":"2022","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013313","article-title":"Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era","volume":"9","author":"Fatola","year":"2025","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017023","article-title":"Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy","volume":"141","author":"Doyle","year":"2023","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13586","article-title":"Prognostic risk stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007\u20132012","volume":"56","author":"Goel","year":"2016","journal-title":"Transfusion"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102388","article-title":"A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura","volume":"8","author":"Abou-Ismail","year":"2024","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:40:25Z","timestamp":1768372825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1645558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2025.1645558"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1645558","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1645558"}}